Radke’s August 4 sale puts Accelerant against Goosehead

The sector backdrop matters because specialty insurance has not been short of growth. U.S. MGA written premiums rose 16% to $114.1 billion in 2024, and excess-and-surplus lines climbed 12.3% to $135 billion, but the pace has started to cool as competition tightens and rate momentum eases into 2026. That is the right frame for Accelerant, which sells a data-heavy risk exchange rather than a plain-vanilla brokerage story, and it is also the right frame for Goosehead, the cleaner public comparator in distribution terms. Both names live in the same broad insurance ecosystem, but they do not earn their keep the same way.

Goosehead is the easier public read because the market knows what to do with a distribution platform. Accelerant is messier. It sits closer to the capital and data plumbing of specialty insurance, where the pitch is efficiency, real-time information sharing, and better matching of risk capital with underwriting talent. That model can scale, but it also leaves you more exposed to whether the market believes the platform is widening its edge or just riding a favorable underwriting cycle. The stock near $12, well below its 52-week high of $30.48, says the market has already made a judgment about that question.

Radke sold again, and the timing is not subtle

Radke’s August 3 sale of 80,000 Class A shares at a weighted-average $12.0566, with trades ranging from $11.815 to $12.235, is the filing that matters here. The euro-normalised filing value was roughly EUR 964,528, and the sale went through Badly Bent LLC under a Rule 10b5-1 plan adopted on March 24, 2026. The Form 4 landed the following day. On its own, that would be a routine executive disposal. In context, it is the second leg of a pattern, because Radke also sold 95,223 shares on July 27 at weighted averages in the mid-$14 range.

That sequence is why the comparison with Goosehead is useful. Goosehead has its own insider and ownership dynamics, but it does not carry the same kind of founder-CEO selling cadence in the public record that Accelerant has shown over the last couple of weeks. When a co-founder and chief executive keeps filing sales while the stock is already sitting near the lower end of its recent range, you do not need to invent a motive to see the market’s problem. You only need to notice that the person with the most intimate view of the business has been reducing exposure into weakness, not into strength.

Radke’s direct and indirect holdings after the August transaction stood at approximately 28.6 million shares on a fully diluted basis. That is still a large stake. It also means the sale did not empty the tank. The point is narrower than that. He sold into a stock that has already been cut down from its highs, and he did it again after a prior July sale. If you are trying to decide whether the market is overreacting to a single filing, the answer is no. This is a sequence.

Why the Accelerant insider cluster stands out

InsiderTrades data flags Accelerant as a cluster name, with four distinct insiders and 12 recent declarations. The recent list includes Radke selling on August 4, Radke selling again on August 3, Francis James ONeill selling on July 29, and more Radke sales on July 28. That is not a random scatter of filings. It is a concentrated run of disposals across a short window, and it gives the stock a different feel from a one-off executive trim.

Goosehead, by contrast, is the cleaner operating comparison but the less interesting insider comparison. It gives you a public peer with a more straightforward distribution model, while Accelerant gives you a platform story where insider behavior becomes part of the valuation debate. If the market is willing to pay up for a specialty insurance platform, it usually wants evidence that management is leaning in. Here, management has been leaning out, at least in the filing record. That does not tell you the business is broken. It does tell you the stock is not getting the kind of internal vote of confidence that tends to help a rerating.

Our scoring lands at 52, and the reason is plain enough. The filing came from a chief executive, it sits inside a cluster, and the size is not trivial relative to the company, at about 0.04% of market value. That is a decent-sized disposal for a name with a market cap of about EUR 2.30 billion. The score is a screen, not a verdict, but it is doing what it should here, which is separating a routine sale from a pattern that deserves a harder look.

Accelerant’s model is more ambitious than Goosehead’s, and that cuts both ways

Accelerant describes itself as a data-driven risk exchange that connects specialty insurance MGAs and underwriters with risk capital providers. The company’s pitch is that better data sharing and technology reduce friction in a traditional value chain that has historically been slow, fragmented, and relationship-heavy. That is a more ambitious model than Goosehead’s brokerage-led public profile, and it is also a more fragile one in the market’s eyes. Platforms get rewarded when investors believe they are becoming indispensable. They get punished when the market starts to think they are simply intermediating a good cycle.

The fundamental backdrop in our dossier is not flattering enough to carry the stock on its own. InsiderTrades data gives Accelerant a fundamental score of 32, with a rank of 21949 out of 28005. The value pillar sits at 34 and quality at 30. Those are not disaster numbers, but they are not the kind of marks that make a selling cluster easy to ignore either. Goosehead does not need to be perfect for the comparison to matter. It only needs to remind you that public insurance platforms can trade on very different assumptions about growth durability, margin structure, and how much of the cycle is already in the price.

The market has already done some of that work for you. Financial stocks have participated in recent gains, and the sector has had a constructive backdrop as investors focus on earnings and rate-sensitive businesses. That helps a name like Accelerant at the margin. It does not erase the fact that the stock is still far below its 52-week high. If the sector is helping, the company-specific tape is still doing the heavier work.

The August 13 print is the next test, not the filing

Accelerant is scheduled to report second-quarter 2026 results on August 13, and that is the next real catalyst. The insider sale matters because it arrives just ahead of that print, after a prior July disposal, and while the stock is already trading near $12. If the company can show that the platform is still gaining traction, the market may decide the selling was just a planned liquidity event under a 10b5-1 program. If the quarter disappoints, the filing will look less like background noise and more like a warning that management preferred to lighten up before the numbers hit.

Goosehead gives you a useful contrast here too. A distribution business can sometimes absorb a softer quarter if the market still trusts the operating cadence. Accelerant has a harder job because its valuation case leans more on the quality of the platform and the durability of the network effect. That makes the August 13 report more important than the filing itself. The filing is the setup. The quarter decides whether the market keeps giving the benefit of the doubt.

Analyst coverage has still leaned constructive, with Buy ratings and targets that have ranged from the mid-teens to $19 in reports issued through mid-2026, though some targets have been cut more recently. That is enough to keep the stock in the conversation, but not enough to neutralize a cluster of insider sales. Analysts can model the upside. Insiders can choose when to sell. The two do not have to agree, and right now they do not.

What the filing shows, and what it leaves open

The August sale was not a balance-sheet event, and it was not a panic exit. It was a planned disposal under a 10b5-1 arrangement, and Radke still held about 28.6 million shares after the trade. That matters. So does the fact that the sale size, while meaningful, is not a controlling stake reduction. You should not read this as a founder abandoning the company. You should read it as a founder who has been willing to sell into a weak share price, twice in a short span, while the stock remains well below its highs.

That is where the comparison with Goosehead earns its keep. Goosehead is the steadier public peer, the one that helps you separate a sector premium from a company-specific discount. Accelerant is the one with the more interesting insider trail, but also the more complicated business model and the weaker fundamental score in our dossier. Put those together and the filing looks less like a curiosity and more like a reminder that the market is still asking whether the platform deserves a premium at all.

The historical cohort data is not cheering or condemning the trade. For chief-executive buys at mid-cap names, the 90-day win rate is 49.7% and the average return is 2.01%. That is a useful anchor because it keeps you honest about how noisy insider data can be. It also keeps you from over-reading a single filing. But this is a sell, not a buy, and the cohort is there to show how similar executive-level activity has behaved over time, not to forecast what Accelerant does next.

Goosehead keeps the bar high, and Accelerant has to clear it on August 13

If you want the simplest head-to-head, Goosehead is the steadier public insurance platform and Accelerant is the more experimental one. Goosehead gives the market a cleaner distribution story. Accelerant gives it a capital-and-data exchange story that depends on execution, adoption, and trust from both sides of the market. That is why insider behavior matters more here than it might at a more mature peer. When the founder-CEO sells twice in a month, the market notices because the stock still needs confidence more than it needs another slogan.

The next few sessions should tell you whether the market is willing to look through the filings or whether it wants to press the issue into earnings. The stock is already near $12, the 52-week high sits at $30.48, and the August 13 report is close enough that the comparison with Goosehead will keep getting sharper, not softer. If Accelerant can show real operating progress, the sales may fade into the background. If it cannot, the cluster will stay in front of the chart.

Dig deeper: Accelerant Holdings's full insider filing history and RADKE JEFFREY L's filing track record.

This is not investment advice.